3SBio Full Year 2024 Earnings: Beats Expectations

Simply Wall St

May 05, 2025

3SBio (HKG:1530) Full Year 2024 Results

Key Financial Results

Revenue: CN¥9.11b (up 17% from FY 2023).
Net income: CN¥2.09b (up 35% from FY 2023).
Profit margin: 23% (up from 20% in FY 2023). The increase in margin was driven by higher revenue.
EPS: CN¥0.86 (up from CN¥0.64 in FY 2023).

We've discovered 2 warning signs about 3SBio. View them for free.

1530 Products In Clinical Trials

Phase I: 9.
Phase II: 5.
Phase III: 10.

1530 Post-Clinical Trial Products

Pre-registration: 4.
Approved (during full year): 3.

earnings-and-revenue-growth — SEHK:1530 Earnings and Revenue Growth May 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

3SBio Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates by 2.0%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 3.1% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for 3SBio you should be aware of.

If you're looking to trade 3SBio, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if 3SBio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.